Lipocine Financials
LPCN Stock | USD 4.54 0.09 2.02% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Debt Equity Ratio | 0.0554 | 0.0583 |
|
| |||||
Current Ratio | 12.24 | 8.6871 |
|
|
The financial analysis of Lipocine is a critical element in measuring its lifeblood. Investors should not minimize Lipocine's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Lipocine | Select Account or Indicator |
Understanding current and past Lipocine Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Lipocine's financial statements are interrelated, with each one affecting the others. For example, an increase in Lipocine's assets may result in an increase in income on the income statement.
Lipocine Stock Summary
Lipocine competes with Reviva Pharmaceuticals, ZyVersa Therapeutics, Unicycive Therapeutics, Checkpoint Therapeutics, and Mustang Bio. Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The companys pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression LPCN 2101 for women with epilepsy, which has completed pre-clinical study and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birthSpecialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US53630X1046 |
CUSIP | 53630X104 53630X203 |
Location | United States; U.S.A |
Business Address | 675 Arapeen Drive, |
Sector | Pharmaceuticals |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.lipocine.com |
Phone | 801 994 7383 |
Currency | USD - US Dollar |
Lipocine Key Financial Ratios
Return On Equity | -0.34 | ||||
Profit Margin | (1.77) % | ||||
Operating Margin | (36.76) % | ||||
Price To Sales | 5.06 X | ||||
Revenue | (2.85 M) |
Lipocine Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 19.7M | 25.4M | 52.5M | 37.5M | 23.0M | 29.7M | |
Other Current Liab | 449.3K | 1.7M | 2.0M | 1.1M | 1.2M | 1.5M | |
Net Debt | (2.6M) | (13.6M) | (639.7K) | (3.1M) | (4.8M) | (5.0M) | |
Retained Earnings | (151.1M) | (172.0M) | (172.7M) | (183.4M) | (199.8M) | (189.8M) | |
Accounts Payable | 1.2M | 1.6M | 1.3M | 600.4K | 1.4M | 798.8K | |
Cash | 9.7M | 19.2M | 3.0M | 3.1M | 4.8M | 9.2M | |
Other Current Assets | 545.9K | 5.7M | 1.5M | 945.3K | 773.4K | 1.5M | |
Total Liab | 13.4M | 10.0M | 6.9M | 1.9M | 2.6M | 5.1M | |
Total Current Assets | 19.6M | 25.3M | 46.4M | 34.1M | 22.9M | 28.8M | |
Common Stock | 3.8K | 7.0K | 8.8K | 8.9K | 8.9K | 9.3K | |
Net Tangible Assets | 6.3M | 15.3M | 45.6M | 35.6M | 41.0M | 27.0M | |
Capital Surpluse | 147.5M | 157.4M | 187.4M | 218.3M | 251.0M | 143.4M | |
Net Receivables | 16.5K | 391.0 | 247.3K | 659.9K | 52.3K | 49.6K | |
Net Invested Capital | 13.4M | 20.9M | 47.9M | 35.6M | 20.4M | 27.8M | |
Net Working Capital | 14.7M | 18.7M | 40.8M | 32.5M | 20.2M | 25.5M | |
Capital Stock | 3.8K | 7.0K | 8.8K | 8.9K | 8.9K | 7.2K |
Lipocine Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | 1.7M | 9.5M | (21.3M) | 197.9K | 1.6M | 1.7M | |
Free Cash Flow | (11.7M) | (15.3M) | (4.4M) | (12.1M) | (11.9M) | (12.5M) | |
Other Non Cash Items | 221.2K | 109.3K | 53.8K | (932.1K) | 1.8M | 1.9M | |
Net Income | (13.0M) | (21.0M) | (634.4K) | (10.8M) | (16.4M) | (17.2M) | |
End Period Cash Flow | 14.7M | 24.2M | 3.0M | 3.1M | 4.8M | 4.5M | |
Change To Netincome | 799.4K | 4.0M | 248.1K | (296.0K) | (340.4K) | (323.4K) | |
Depreciation | 15.4K | 3.6K | 380.0 | 9.5K | 28.7K | 30.1K | |
Investments | 3.0M | 3.9M | (43.8M) | 14.3M | 13.0M | 13.6M | |
Change Receivables | (15.4K) | 22.0K | 16.1K | (246.9K) | (222.2K) | (211.1K) | |
Net Borrowings | (3.3M) | (1.4M) | (3.3M) | (2.3M) | (2.1M) | (2.0M) |
Lipocine Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Lipocine's current stock value. Our valuation model uses many indicators to compare Lipocine value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lipocine competition to find correlations between indicators driving Lipocine's intrinsic value. More Info.Lipocine is rated second overall in return on equity category among its peers. It is rated third overall in return on asset category among its peers . At this time, Lipocine's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lipocine's earnings, one of the primary drivers of an investment's value.Lipocine Systematic Risk
Lipocine's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Lipocine volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Lipocine correlated with the market. If Beta is less than 0 Lipocine generally moves in the opposite direction as compared to the market. If Lipocine Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Lipocine is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Lipocine is generally in the same direction as the market. If Beta > 1 Lipocine moves generally in the same direction as, but more than the movement of the benchmark.
Lipocine Thematic Clasifications
Lipocine is part of several thematic ideas from IT to Biotech. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic IdeasToday, most investors in Lipocine Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Lipocine's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Lipocine growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Lipocine November 30, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Lipocine help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Lipocine. We use our internally-developed statistical techniques to arrive at the intrinsic value of Lipocine based on widely used predictive technical indicators. In general, we focus on analyzing Lipocine Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Lipocine's daily price indicators and compare them against related drivers.
Downside Deviation | 4.95 | |||
Information Ratio | 0.06 | |||
Maximum Drawdown | 27.84 | |||
Value At Risk | (6.20) | |||
Potential Upside | 7.08 |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.75) | Revenue Per Share 0.903 | Quarterly Revenue Growth 137.519 | Return On Assets (0.23) | Return On Equity (0.34) |
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipocine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.